线上论坛邀请函——高通量药物筛选前沿技术最新动态- 大数跨境

进科驰安

2022-01-06

导读：1月12号，不见不散

精彩前沿，不容错过

随着技术不断进步，当前生命科学基础研究和新药研发都得到了飞速发展。特别是在新药研发领域，不仅生物大分子药已开始大行其道，小分子药物也随着PROTAC的出现掀起了小分子药物研发的新浪潮。当前的新药研发对于高通量，快速和精准的分析方案有着迫切的需求。如何在快速发展，激烈竞争的创新药研发过程中，加速提质创新，提升药物研发的成功率，已成为当前最引人注目的焦点。

此次网络论坛，诚邀国际多位行业专家，共话创新，分享讨论高通量药物筛选前沿技术最新动态趋势。

受邀出席专家来自

>>德国BMG LABTECH公司——专注高通量药筛领域的多功能酶标仪厂家

>>瑞士Creoptix公司——创新研发出GCI超灵敏超快速分析无标记分子相互作用的厂家

>>英国Domainex公司——对难靶向酶开发极具经验的CRO

在此，我们诚邀您报名参与，希望借此机会与您及业内专家们，一起追踪动态趋势，讨论前沿方案，助力新药研发。

会议时间

2022年01月12日 16:00-18:00

参会方式

扫描或长按以下二维码填表报名

主讲人简介

Ann-Cathrin Volz works as Application Specialist for BMG LABTECH with specific focus on cell-based assays. After her graduation in Nutritional Sciences at the University of Hohenheim she completed her PhD and a Postdoc in the field of Tissue Engineering. In her position, she can draw on her experience in cell culture and related microplate-based assays to support customers in assay optimisation for existing and emerging applications.

Also part of BMG´s Application Specialist team, Martin Mangold focusses on enzyme-based assays. He graduated in biology followed by a Master of Science in the field of drug research. He went on and completed his PhD in the field of medicinal chemistry at the University of Bonn. Now he uses his knowledge of enzyme-based and drug screening microplate assays to support customers with their applications and assay optimisation.

Tatiana Tiago is the Product Manager at Creoptix with over 8 years’ experience in pharma and biotech industry. Her background in molecular biology has given her a wide understanding of binding interaction analysis including label-based and label-free technologies. Tatiana holds a degree in in Medical Molecular Biology from the University of Westminster and a PhD in Neuroscience from the University of Modena and Reggio Emilia. Recently, Tatiana’s focus is to help life-science scientist understand GCI and optimize the label-free WAVEsystem enabling them to accelerate drug discovery.

Trevor Askwith is a cell biologist and biochemist with over 10 years’ experience of small-molecule drug discovery research. He began is drug discovery career as a cell biologist at Novartis where and has more recently worked in academic drug discovery running leading the Assay Development and Screening in the Drug Discovery Group at UCL. Trevor is now the Group Leader for Assay Biology a Domainex responsible of the biophysics, biochemistry and cell biology departments.

Dr Tom Mander has nearly 30 years of small molecule drug discovery and translational research experience in both scientific and commercial roles. After graduating and working at Amersham International plc developing radioimmunoassays, he completed his DPhil studies with Professor John Morris into the roles of microglial cells at the Department of Human Anatomy, University of Oxford in 1992. Tom joined Domainex in April 2015 as Chief Operating Officer to oversee the scientific service operations and business development activities of the company. During his time in this role, he has established a broad portfolio of pharma, biotech, academic and patient foundation clients both in the UK and overseas, launched several new services and has overseen the growth of the company. In April 2020, he took over as Chief Executive Officer after the retirement of Dr Trevor Perrior.

BMG LABTECH为德国多功能酶标仪制造商，多年来专注研发酶标仪技术，特别是为科研单位，药企和CRO的高通量药筛应用带来强大的优势。BMG高端PHERAstar系统在药筛领域近年更是受到诸多认可。

瑞士Creoptix，拥有基于光栅耦合干涉技术（Grating-Coupled Interferometry ，GCI）的光学生物传感器专利，以及外置的微流体的独特设计和Google公司研发的自动化软件。致力于提供高质量的动力学数据，拥有业内最灵敏准确的WAVEsystem无标记分子相互作用仪，使全球生物科学研究者可以做以前不可能做的事情，看到以前看不见的数据。凭借突破性的创新，避开了SPR的局限性，突破无标记技术的局限。

Domainex是一家英国老牌综合性药物发现服务公司，针对难靶向的酶开发一流。

推荐阅读

BMG多功能酶标仪国内用户出版物快报 (2021年11月)

电子书福利：药物研发中的结合动力学

MINI TALKS：让核酸质量评估变得更简单快速

BMG：专业研究的高阶应用魔方

BMG多功能酶标仪国内用户出版物快报 (2021年10月)

BMG PA-QuIC助力国家疾控中心开展东亚最大规模的遗传性朊病毒病研究

技术讲座：BMG酶标仪助力治疗COVID-19药物文库筛选

BMG多功能酶标仪国内用户出版物快报 (2021年9月)

BMG多功能酶标仪国内用户出版物快报 (2021年8月)

BMG与MED64打造神经退行性疾病研究的黄金组合